On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric antigen receptor...
bluebird bio, Inc. announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of...
REGENXBIO Inc. is celebrating the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility.
Also Read: Updated Data for Janssen’s Bispecific Teclistamab Suggest...
Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced multiple major milestones for ATA-100 and ATA-200,...
Juniper Biologics, a science-led healthcare company focused on researching, developing and commercializing novel therapies announced that it has gained the licensing rights to develop...
